Incidence and clinical significance of CDKN2/MTS1/P16(ink4a) and MTS2/P15(ink4b) gene deletions in childhood acute lymphoblastic leukemia

Muxiang Zhou, Lubing Gu, Andrew M Yeager, Harry W. Findley

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We have examined the incidence and clinical significance of deletions of two candidate tumor suppressor genes, CDKN2/MTS1/p16(ink4A) and MTS2/p15(ink4B), in pediatric acute lymphoblastic leukemia (ALL). Gene deletion was evaluated in leukemic bone marrow (BM) cells obtained at diagnosis from 105 pediatric ALL patients: 83 with B-cell precursor (BCP- ALL) ALL and 22 with T-ALL. CDKN2/p16 deletion was seen in 23 of the 83 (28%) BCP-ALL and 15 of the 22 (68%) T-ALL cases. A virtually identical pattern of MTS2/p15 deletion was detected in these patients: p15 was deleted in 37 of 38 cases with p16 deletion, and p15 was not deleted in any p16-positive specimens. P16/p15 deletions were significantly related to poor prognosis factors including age under 1 year (P < 0.001), initial white cell counts greater than 50 x 109 per liter (P < .001), and T cell phenotype P < .005). Analysis of all 105 patients revealed that the 5-year disease-free survival rate was 68% for patients without p16/p15 deletions and 35% for those with p16/p15 deletions (P < .005). The association between gene deletion at initial diagnosis and unfavorable outcome suggests that loss of these genes is clinically significant and indicates a need for prospective studies of p16/p15 deletion in pediatric ALL patients.

Original languageEnglish (US)
Pages (from-to)141-150
Number of pages10
JournalPediatric Hematology and Oncology
Volume14
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Gene Deletion
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Genes
Incidence
Cells
T-cells
Tumors
Bone
B-Lymphoid Precursor Cells
Gene
Childhood
Age Factors
Tumor Suppressor Genes
Bone Marrow Cells
Disease-Free Survival
Survival Rate
Cell Count
Prospective Studies
T-Lymphocytes

Keywords

  • p16/p15gene deletion
  • pediatric acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Incidence and clinical significance of CDKN2/MTS1/P16(ink4a) and MTS2/P15(ink4b) gene deletions in childhood acute lymphoblastic leukemia. / Zhou, Muxiang; Gu, Lubing; Yeager, Andrew M; Findley, Harry W.

In: Pediatric Hematology and Oncology, Vol. 14, No. 2, 1997, p. 141-150.

Research output: Contribution to journalArticle

@article{db6fcfaf331c4e31bda34e0cc3fceef8,
title = "Incidence and clinical significance of CDKN2/MTS1/P16(ink4a) and MTS2/P15(ink4b) gene deletions in childhood acute lymphoblastic leukemia",
abstract = "We have examined the incidence and clinical significance of deletions of two candidate tumor suppressor genes, CDKN2/MTS1/p16(ink4A) and MTS2/p15(ink4B), in pediatric acute lymphoblastic leukemia (ALL). Gene deletion was evaluated in leukemic bone marrow (BM) cells obtained at diagnosis from 105 pediatric ALL patients: 83 with B-cell precursor (BCP- ALL) ALL and 22 with T-ALL. CDKN2/p16 deletion was seen in 23 of the 83 (28{\%}) BCP-ALL and 15 of the 22 (68{\%}) T-ALL cases. A virtually identical pattern of MTS2/p15 deletion was detected in these patients: p15 was deleted in 37 of 38 cases with p16 deletion, and p15 was not deleted in any p16-positive specimens. P16/p15 deletions were significantly related to poor prognosis factors including age under 1 year (P < 0.001), initial white cell counts greater than 50 x 109 per liter (P < .001), and T cell phenotype P < .005). Analysis of all 105 patients revealed that the 5-year disease-free survival rate was 68{\%} for patients without p16/p15 deletions and 35{\%} for those with p16/p15 deletions (P < .005). The association between gene deletion at initial diagnosis and unfavorable outcome suggests that loss of these genes is clinically significant and indicates a need for prospective studies of p16/p15 deletion in pediatric ALL patients.",
keywords = "p16/p15gene deletion, pediatric acute lymphoblastic leukemia",
author = "Muxiang Zhou and Lubing Gu and Yeager, {Andrew M} and Findley, {Harry W.}",
year = "1997",
language = "English (US)",
volume = "14",
pages = "141--150",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Incidence and clinical significance of CDKN2/MTS1/P16(ink4a) and MTS2/P15(ink4b) gene deletions in childhood acute lymphoblastic leukemia

AU - Zhou, Muxiang

AU - Gu, Lubing

AU - Yeager, Andrew M

AU - Findley, Harry W.

PY - 1997

Y1 - 1997

N2 - We have examined the incidence and clinical significance of deletions of two candidate tumor suppressor genes, CDKN2/MTS1/p16(ink4A) and MTS2/p15(ink4B), in pediatric acute lymphoblastic leukemia (ALL). Gene deletion was evaluated in leukemic bone marrow (BM) cells obtained at diagnosis from 105 pediatric ALL patients: 83 with B-cell precursor (BCP- ALL) ALL and 22 with T-ALL. CDKN2/p16 deletion was seen in 23 of the 83 (28%) BCP-ALL and 15 of the 22 (68%) T-ALL cases. A virtually identical pattern of MTS2/p15 deletion was detected in these patients: p15 was deleted in 37 of 38 cases with p16 deletion, and p15 was not deleted in any p16-positive specimens. P16/p15 deletions were significantly related to poor prognosis factors including age under 1 year (P < 0.001), initial white cell counts greater than 50 x 109 per liter (P < .001), and T cell phenotype P < .005). Analysis of all 105 patients revealed that the 5-year disease-free survival rate was 68% for patients without p16/p15 deletions and 35% for those with p16/p15 deletions (P < .005). The association between gene deletion at initial diagnosis and unfavorable outcome suggests that loss of these genes is clinically significant and indicates a need for prospective studies of p16/p15 deletion in pediatric ALL patients.

AB - We have examined the incidence and clinical significance of deletions of two candidate tumor suppressor genes, CDKN2/MTS1/p16(ink4A) and MTS2/p15(ink4B), in pediatric acute lymphoblastic leukemia (ALL). Gene deletion was evaluated in leukemic bone marrow (BM) cells obtained at diagnosis from 105 pediatric ALL patients: 83 with B-cell precursor (BCP- ALL) ALL and 22 with T-ALL. CDKN2/p16 deletion was seen in 23 of the 83 (28%) BCP-ALL and 15 of the 22 (68%) T-ALL cases. A virtually identical pattern of MTS2/p15 deletion was detected in these patients: p15 was deleted in 37 of 38 cases with p16 deletion, and p15 was not deleted in any p16-positive specimens. P16/p15 deletions were significantly related to poor prognosis factors including age under 1 year (P < 0.001), initial white cell counts greater than 50 x 109 per liter (P < .001), and T cell phenotype P < .005). Analysis of all 105 patients revealed that the 5-year disease-free survival rate was 68% for patients without p16/p15 deletions and 35% for those with p16/p15 deletions (P < .005). The association between gene deletion at initial diagnosis and unfavorable outcome suggests that loss of these genes is clinically significant and indicates a need for prospective studies of p16/p15 deletion in pediatric ALL patients.

KW - p16/p15gene deletion

KW - pediatric acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0030941174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030941174&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 141

EP - 150

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 2

ER -